Kintor Pharmaceutical Limited (HKG:9939)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.050
+0.970 (31.49%)
At close: Mar 10, 2026
249.14%
Market Cap 1.52B
Revenue (ttm) 12.04M
Net Income (ttm) -183.07M
Shares Out 493.52M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,422,500
Average Volume 2,426,275
Open 3.120
Previous Close 3.080
Day's Range 3.120 - 4.050
52-Week Range 1.050 - 4.050
Beta -0.58
RSI 73.84
Earnings Date Mar 26, 2026

About Kintor Pharmaceutical

Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People’s Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 136
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9939
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.